Extended Data Table 2 Baseline radiologic characteristics of participants in the PET/CT post-hoc exploratory analysis

From: A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial

  1. This table includes the baseline radiologic characteristics, such as the lesion volume and number of cavities, of 19 participants included in the PET/CT post-hoc exploratory analysis.
Back to article page